Evidence map›Paper›PMID 41039626›Full record

ArticleChinese medicine2025

Synergistic potential of Berberine and Wogonin improved adipose inflammation and insulin resistance associated with obesity through HIF-α axis.

Zihan Zhou, Mingsu Wang, Xiaoyu Zhang, Yinyue Xu, Ping Li, Zuguo Zheng, Hua Yang

Abstract read
In one paragraph

Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Frontiers in genetics · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zihan Zhou *State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 211198, China.
Mingsu Wang *State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 211198, China.
Xiaoyu ZhangState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 211198, China.
Yinyue XuState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 211198, China.
Ping LiState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 211198, China. liping2004@126.com.
Zuguo ZhengState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 211198, China. zhengzuguo@foxmail.com.
Hua YangState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 211198, China. yanghuacpu@126.com.

Funding

Jiangsu Province Traditional Chinese Medicine Science and Technology Development Program QN202426the Chief Scientist Research Project of Hubei Shizhen Laboratory HSL2024SX0005the National Key R&D Program of China 2022YFC3500300the National Natural Science Foundation of China 82130114the National Science and Technology Major Project on Key New Drug Creation and Development Program 2019ZX09201005-007
6 · The paper itself

Abstract

backgroundObesity-induced adipose hypoxia activates the hypoxia-inducible factor alpha (HIF-α) axis, where HIF-1α and HIF-2α exhibit functional antagonism: HIF-1α exacerbates insulin resistance (IR) and inflammation, whereas HIF-2α counteracts these effects. This dichotomy suggests dual targeting (inhibiting HIF-1α/activating HIF-2α) could synergistically ameliorate obesity-associated IR. Coptidis Rhizoma and Scutellariae Radix, a classic traditional Chinese medicine (TCM) pair for damp-heat obesity-demonstrate efficacy, but their synergistic components and mechanistic basis remain unclear. Therefore, this study aims to identify active ingredients through the dual targeting strategy and subsequently validate their therapeutic efficacy.

methodsBased on the dual-targeting strategy, potential active ingredients were identified using a specifically designed dual-luciferase reporter system that simultaneously inhibits HIF-1α and activates HIF-2α. The optimal synergistic ratio was determined by applying the Loewe model. In vitro anti-inflammatory efficacy was evaluated in macrophages stimulated with palmitic acid or lipopolysaccharide. In vivo effects were assessed in a high-fat diet-induced obese mouse. Insulin sensitivity was determined by measuring fasting blood glucose levels and performing oral glucose tolerance test and insulin tolerance tests. Tissues were analysed for lipid metabolism and inflammatory markers via immunohistochemistry, quantitative real-time PCR, and enzyme-linked immunosorbent assay.

resultsBerberine (BBR) and wogonin (WOG) were identified from herb pair to inhibit HIF-1α and activate HIF-2α in an optimal synergistic ratio of 3:1. At this ratio, the combination significantly ameliorated the secretion of pro-inflammatory cytokines in vitro. Consistent with the in vitro findings, co-administration of BBR and WOG (3:1) showed lipid-lowering effects comparable to metformin and effectively improved insulin sensitivity in obese mice. Additionally, improved lipid metabolism-related parameters including plasma total cholesterol and free fatty acids, thereby mitigating hepatic lipid accumulation.

conclusionsThe synergistic constituents of Coptidis Rhizoma-Scutellariae Radix, namely BBR and WOG, synergistically alleviate IR associated with obesity by inhibiting HIF-1α and activating HIF-2α, respectively. This study elucidates the mechanistic basis of herbal combination therapy for metabolic disorders and provides a foundation for developing novel synergistic therapeutics against obesity-related IR.

Indexed as

BerberineHIF-αInsulin resistanceObesitySynergizeWogonin

Identifiers

PMID41039626
PMCPMC12492755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.